company background image
IVA logo

Inventiva NasdaqGM:IVA Stock Report

Last Price

US$2.43

Market Cap

US$230.6m

7D

4.1%

1Y

-34.4%

Updated

02 Feb, 2025

Data

Company Financials +

IVA Stock Overview

A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. More details

IVA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Inventiva S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Inventiva
Historical stock prices
Current Share Price€2.43
52 Week High€4.50
52 Week Low€1.53
Beta0.78
1 Month Change12.29%
3 Month Change-12.12%
1 Year Change-34.45%
3 Year Change-81.60%
5 Year Changen/a
Change since IPO-81.93%

Recent News & Updates

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Jul 08

Recent updates

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Jul 08

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Feb 22

Inventiva, Sino Biopharm sign licensing pact to develop, commercialize NASH treatment

Sep 21

Inventiva lays out trial design for late-stage lanifibranor study in NASH

Jan 05

Shareholder Returns

IVAUS BiotechsUS Market
7D4.1%1.8%-0.8%
1Y-34.4%-2.1%22.7%

Return vs Industry: IVA underperformed the US Biotechs industry which returned -2.1% over the past year.

Return vs Market: IVA underperformed the US Market which returned 22.7% over the past year.

Price Volatility

Is IVA's price volatile compared to industry and market?
IVA volatility
IVA Average Weekly Movement7.1%
Biotechs Industry Average Movement11.2%
Market Average Movement6.4%
10% most volatile stocks in US Market18.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: IVA has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: IVA's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011123Frederic Crenwww.inventivapharma.com

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

Inventiva S.A. Fundamentals Summary

How do Inventiva's earnings and revenue compare to its market cap?
IVA fundamental statistics
Market capUS$230.55m
Earnings (TTM)-US$108.00m
Revenue (TTM)US$19.98m

11.5x

P/S Ratio

-2.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IVA income statement (TTM)
Revenue€19.28m
Cost of Revenue€1.08m
Gross Profit€18.19m
Other Expenses€122.38m
Earnings-€104.19m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Mar 26, 2025

Earnings per share (EPS)-1.09
Gross Margin94.38%
Net Profit Margin-540.52%
Debt/Equity Ratio-85.6%

How did IVA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 13:54
End of Day Share Price 2025/01/31 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Inventiva S.A. is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jean-Jacques Le FurBryan Garnier & Co
Edward NashCanaccord Genuity
Stephanie LefebvreGilbert Dupont